GE HealthCare announced US FDA 510(k) clearance of Allia IGS Pulse – the latest addition to the company’s image guided system (IGS) offerings. Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless of patient size.
Cardiovascular disease (CVD) continues to grow in prevalence, with CVDs being the leading cause of death globally, according to GE HealthCare. As clinicians work to treat CVDs, cardiology procedures continue to evolve as demand for minimally invasive surgery grows.
The new Allia IGS Pulse provides a personalized workspace that meets the operator’s specific needs and preferences. As part of its new image chain, the system features a monopolar x-ray tube used to capture images for interventional procedures. This new tube is powerful, yet quieter than normal conversation to optimize the operating environment during a procedure, according to the company.
The small footprint of the new tube also helps clinicians reach steep angulation for better understanding of coronary artery anatomy, even with the 30cm detector configurations. The latest version of MyIQ technology incorporated into the system allows clinicians to select their favorite image look from four different image styles with one click for a tailored experience at no additional dose.
With Allia IGS Pulse, interventionalists are able to get exceptional image quality for large and bariatric patients with a BMI of greater than 30. The system’s reduced pulse width and X-ray peak power helps to decrease motion blur for better visualization of moving elements such as vessels and devices.
To relieve clinicians and technologists of the complex task of optimizing image quality and dose during procedures, Allia IGS Pulse features the company’s intelligent image chain leveraging AI, AutoRight PLUS. With AutoRight PLUS, the system now optimizes seven parameters in real time, including Focal Spot Shape. To further optimize dose along the image chain, a unique suite of tools is also available to help support dose efficiency, dose reduction and dose awareness.
Since January 2023, Allia IGS Pulse has been in pilot operations at Clinique Pasteur – Toulouse in Toulouse, France.
“Interventional cardiology procedures require exceptional image quality,” said Arnaud Marie – general manager of interventional for GE HealthCare. “I’m excited by the addition of Allia IGS Pulse to our interventional offerings because it addresses the very things clinicians continue to tell us present challenges in their day-to-day practice. By developing new features to further evolve our core platform, we’re helping to reduce complexity and improve the operating environment so that clinicians can have a personalized workspace that better enables them to keep their focus where it belongs – on their patients.”
